1. Home
  2. SSKN vs LYRA Comparison

SSKN vs LYRA Comparison

Compare SSKN & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSKN
  • LYRA
  • Stock Information
  • Founded
  • SSKN 1989
  • LYRA 2005
  • Country
  • SSKN United States
  • LYRA United States
  • Employees
  • SSKN N/A
  • LYRA N/A
  • Industry
  • SSKN Medical/Dental Instruments
  • LYRA Medical/Dental Instruments
  • Sector
  • SSKN Health Care
  • LYRA Health Care
  • Exchange
  • SSKN Nasdaq
  • LYRA Nasdaq
  • Market Cap
  • SSKN 12.5M
  • LYRA 11.0M
  • IPO Year
  • SSKN 2005
  • LYRA 2020
  • Fundamental
  • Price
  • SSKN $3.05
  • LYRA $0.17
  • Analyst Decision
  • SSKN
  • LYRA Buy
  • Analyst Count
  • SSKN 0
  • LYRA 5
  • Target Price
  • SSKN N/A
  • LYRA $4.50
  • AVG Volume (30 Days)
  • SSKN 4.7K
  • LYRA 1.7M
  • Earning Date
  • SSKN 11-13-2024
  • LYRA 11-12-2024
  • Dividend Yield
  • SSKN N/A
  • LYRA N/A
  • EPS Growth
  • SSKN N/A
  • LYRA N/A
  • EPS
  • SSKN N/A
  • LYRA N/A
  • Revenue
  • SSKN $32,674,999.00
  • LYRA $1,471,000.00
  • Revenue This Year
  • SSKN $0.94
  • LYRA N/A
  • Revenue Next Year
  • SSKN $11.30
  • LYRA N/A
  • P/E Ratio
  • SSKN N/A
  • LYRA N/A
  • Revenue Growth
  • SSKN N/A
  • LYRA 3.37
  • 52 Week Low
  • SSKN $2.51
  • LYRA $0.16
  • 52 Week High
  • SSKN $6.50
  • LYRA $6.79
  • Technical
  • Relative Strength Index (RSI)
  • SSKN 55.69
  • LYRA 36.11
  • Support Level
  • SSKN $2.96
  • LYRA $0.19
  • Resistance Level
  • SSKN $3.15
  • LYRA $0.21
  • Average True Range (ATR)
  • SSKN 0.12
  • LYRA 0.02
  • MACD
  • SSKN 0.01
  • LYRA -0.00
  • Stochastic Oscillator
  • SSKN 79.31
  • LYRA 6.42

About SSKN Strata Skin Sciences Inc.

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: